1. Postic, C. & Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118, 829-838 (2008).
2. Perry, R.J., Samuel, V.T., Petersen, K.F. & Shulman, G.I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84-91 (2014).
3. Chong, M.F., Fielding, B.A. & Frayn, K.N. Metabolic interaction of dietary sugars and plasma lipids with a focus on mechanisms and de novo lipogenesis. Proc Nutr Soc 66, 52-59 (2007).
4. Palmisano, B.T., Zhu, L. & Stafford, J.M. Role of Estrogens in the Regulation of Liver Lipid Metabolism. Adv Exp Med Biol 1043, 227-256 (2017).
5. Yao, X., et al. Regulation of fatty acid composition and lipid storage by thyroid hormone in mouse liver. Cell Biosci 4, 38 (2014).
6. Antherieu, S., Rogue, A., Fromenty, B., Guillouzo, A. & Robin, M.A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 53, 1895-1905 (2011).
7. Estes, C., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 69, 896-904 (2018).
8. Kim, C.W., et al. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab 26, 394-406 e396 (2017).
9. Loomba, R., et al. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 155, 1463-1473 e1466 (2018).
10. Loomba, R., et al. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology (2021).
11. Calle, R.A., et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med 27, 1836-1848 (2021).
12. Palomer, X., Pizarro-Delgado, J., Barroso, E. & Vazquez-Carrera, M. Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. Trends Endocrinol Metab 29, 178-190 (2018).
13. Marcelino, H., et al. A role for adipose tissue de novo lipogenesis in glucose homeostasis during catch-up growth: a Randle cycle favoring fat storage. Diabetes 62, 362-372 (2013).
14. Akazawa, Y., et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol 52, 586-593 (2010).
15. Cao, H., et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 134, 933-944 (2008).
16. Chirala, S.S., et al. Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci U S A 100, 6358-6363 (2003).
17. Lek, M., et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285-291 (2016).
18. Roumans, K.H.M., et al. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat Commun 11, 1891 (2020).
19. Murphy, E.J. Stable isotope methods for the in vivo measurement of lipogenesis and triglyceride metabolism. J Anim Sci 84 Suppl, E94-104 (2006).
20. Aarsland, A. & Wolfe, R.R. Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. J Lipid Res 39, 1280-1286 (1998).
21. Eissing, L., et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat Commun 4, 1528 (2013).
22. Donnelly, K.L., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351 (2005).
23. Lee, W.N., et al. In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis. Am J Physiol 266, E699-708 (1994).
24. O'Hea, E.K. & Leveille, G.A. Significance of adipose tissue and liver as sites of fatty acid synthesis in the pig and the efficiency of utilization of various substrates for lipogenesis. J Nutr 99, 338-344 (1969).
25. Marra, F. & Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68, 280-295 (2018).
26. Yahagi, N., et al. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem 274, 35840-35844 (1999).
27. Dentin, R., et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J Clin Invest 115, 2843-2854 (2005).
28. Sanders, T.A., Sullivan, D.R., Reeve, J. & Thompson, G.R. Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia. Arteriosclerosis 5, 459-465 (1985).
29. Skulas-Ray, A.C., et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation 140, e673-e691 (2019).
30. Blaton, V., et al. Effect of polyunsaturated isocaloric fat diets on plasma lipids, apolipoproteins and fatty acids. Atherosclerosis 53, 9-20 (1984).
31. Sekiya, M., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38, 1529-1539 (2003).
32. Lee, C.H., Fu, Y., Yang, S.J. & Chi, C.C. Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis. Nutrients 12(2020).
33. Capanni, M., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23, 1143-1151 (2006).
34. Spadaro, L., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 40, 194-199 (2008).
35. Bjermo, H., et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 95, 1003-1012 (2012).
36. Argo, C.K., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 62, 190-197 (2015).
37. Manson, J.E., et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 380, 23-32 (2019).
38. Bhatt, D.L., et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 380, 11-22 (2019).
39. Nicholls, S.J., et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 324, 2268-2280 (2020).
40. Lin, H.P., et al. Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth. Cancer Res 76, 6924-6936 (2016).
41. James, A.M., et al. Non-enzymatic N-acetylation of Lysine Residues by AcetylCoA Often Occurs via a Proximal S-acetylated Thiol Intermediate Sensitive to Glyoxalase II. Cell Rep 18, 2105-2112 (2017).
42. Ortega-Prieto, P. & Postic, C. Carbohydrate Sensing Through the Transcription Factor ChREBP. Front Genet 10, 472 (2019).
43. Bowers, M., et al. FASN-Dependent Lipid Metabolism Links Neurogenic Stem/Progenitor Cell Activity to Learning and Memory Deficits. Cell Stem Cell 27, 98-109 e111 (2020).
44. Niwa, H., et al. ChREBP Rather Than SHP Regulates Hepatic VLDL Secretion. Nutrients 10(2018).
45. Rong, X., et al. ER phospholipid composition modulates lipogenesis during feeding and in obesity. J Clin Invest 127, 3640-3651 (2017).
46. Sagar, G.D., et al. Ubiquitination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activity. Mol Cell Biol 27, 4774-4783 (2007).
47. Wang, H., et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 431, 873-878 (2004).
48. Bergman, A., et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study. Clin Pharmacol Drug Dev 9, 514-526 (2020).
49. Matyash, V., Liebisch, G., Kurzchalia, T.V., Shevchenko, A. & Schwudke, D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res 49, 1137-1146 (2008).
Additional references for methods section:
50. Barr, J., et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res 11, 2521-2532 (2012).
51. Schlein, C., et al. FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues. Cell Metab 23, 441-453 (2016).
52. McDonald, J.G., Thompson, B.M., McCrum, E.C. & Russell, D.W. Extraction and analysis of sterols in biological matrices by high performance liquid chromatography electrospray ionization mass spectrometry. Methods Enzymol 432, 145-170 (2007).
53. Dole, V.P. A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J Clin Invest 35, 150-154 (1956).
54. Maier, T., Leibundgut, M. & Ban, N. The crystal structure of a mammalian fatty acid synthase. Science 321, 1315-1322 (2008).
55. Pettersen, E.F., et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci 30, 70-82 (2021).
56. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J.V. & Mann, M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1, 2856-2860 (2006).
57. Orsburn, B.C. Proteome Discoverer-A Community Enhanced Data Processing Suite for Protein Informatics. Proteomes 9(2021).
58. Tyanova, S., et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13, 731-740 (2016).